| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Oxlumo | |
| 3 | Generic | lumasiran | |
| 4 | Indication | Primary Hyperoxaluria type 1. Oxalate overproduction. | |
| 5 | MOA | Hydroxyacid oxidase 1 RNAi, encodes glycolate oxidase | |
| 6 | Administration | subcutaneous | |
| 7 | Clinical Trials | ||
| 8 | Phase III "ILLUMINATE-C" PH1 with severe renal impairment - NCT04152200 | ||
| 9 | Cohort A n=6 | ||
| 10 | Cohort B n=15 | ||
| 11 | |||
| 12 | Phase III "ILLUMINATE-A" pediatric PH1 | ||
| 13 | |||
| 14 | Phase III "ILLUMINATE-B" adult PH1 |